Skip to content
The Kids Research Institute Australia logo
Donate

Discover . Prevent . Cure .

Search

Research

The future of acute rheumatic fever and rheumatic heart disease in Australia

Globally, ARF and RHD cause more than a quarter of a million deaths and substantial disability each year.

Research

Group A Streptococcal Diseases and Their Global Burden

We review GAS transmission characteristics and prevention strategies, historical and geographical trends and report on the estimated global burden disease...

Research

A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010

Quantification of the disease burden caused by different risks informs prevention by providing an account of health loss different to that provided by a...

Research

Rheumatic Fever Follow-Up Study (RhFFUS) protocol: A cohort study investigating the significance of minor

In Australia, rheumatic heart disease (RHD) is almost exclusively restricted to Aboriginal Australian and Torres Strait Islander people with children being...

Research

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010

Reliable and timely information on the leading causes of death in populations, and how these are changing, is a crucial input into health policy debates.

News & Events

Partnering with communities to reduce rheumatic heart disease in the Kimberley

The Kimberley has the highest rates of rheumatic heart disease (RHD) in Western Australia – but through the establishment of a new community-led, research-backed project known as END RHD Communities, there’s hope this will change.

News & Events

Bold bid to end rheumatic heart disease

Some of the nation’s leading medical researchers will converge on Darwin this week to step out a plan to wipe out rheumatic heart disease.

Research

Acceptability of sonicated versus unsonicated reconstituted (powdered) benzathine penicillin G for rheumatic fever prophylaxis

Jonathan Carapetis AM AM MBBS FRACP FAFPHM PhD FAHMS Executive Director; Co-Head, Strep A Translation; Co-Founder of REACH 08 6319 1000 contact@

Research

Defining target penicillin concentrations for subsequent studies of a reformulated long-acting benzathine penicillin prototype

Jonathan Tim Carapetis AM Barnett AM MBBS FRACP FAFPHM PhD FAHMS PhD Executive Director; Co-Head, Strep A Translation; Co-Founder of REACH Head,